Estrogen ß in tumor cells in men, radically operated for lung cancer, as prognostic factor and potential target of antiestrogen therapy

Aim. Evaluation of prognostic role of estrogen receptors at male patients with NSLC. Methods and materials. 95 clinical cases of male patients who underwent treatment in the National Medical Research Centre of Oncology n.a. N. N. Blokhin (Moscow, Russia) from 2009 to 2016 were studied. All patients had NSLC confirmed by histological analysis and follow-up results were also examined. Results. The low level of estrogen ß receptor expression does not have prognostic value at male patients with adenocarcinoma of the lung. However, an expression of ER ß can be used as a prognostic factor for male patients with locally advanced NSLC: low level of ER ß expression was associated with longer survival rate with comparison to patients with higher ER ß expression (78.0 and 51.0 % correspondingly; p = 0.04). Therefore, the high level of ER ß expression in squamous cell at male patients with NSLC can be a new target for antiestrogen therapy. Conclusion. 1. The level of ER ß expression does not correlate with the prognosis of the disease at male patients with adenocarcinoma and cannot be used as a prognostic factor. 2. The level of ER ß expression prognosticates the relapse-free survival at male patients with locally advanced NSLC after R-0 resection. High level of ER ß expression in the lung tissue of male patients with NSLC allows using it as a target for antiestrogen therapy.

NSLC, prognostic factors, ER ß at lung cancer, relapse-free survival at lung cancer

1. Богуш Т. А., Дудко Е. А., Беме А. А. и др. // Биохимия. 2010. T. 75. № 12. C. 1633-1641.

2. Евразийский онкологический журнал, 2017. // Злокачественные новообразования в России в 2015 году (заболеваемость и смертность).

3. Клинические рекомендации Министерства здравоохранения РФ «Рак легкого», 2017.

4. Полоцкий Б. Е. Уровень экспрессии эстрогеновых рецепторов ß в ткани немелкоклеточного рака и метастазов в легком // Б. Е. Полоцкий, Б. Б. Ахмедов, Е. А. Богуш, Е. А. Дудко, Т. А. Богуш, М. М. Давыдов. DOI: 10.17650/1726-9784-2016-15-4-34-36.

5. Berardi R. Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex. Berardi R., Morgese F., Santinelli A., Onofri A., Biscotti T., Brunelli A., Caramanti M, Savini A., De Lisa M., Ballatore Z., Pompili C., Salati M., Mazzanti P., Torniai M., Cascinu S., Oncotarget. 2016 Dec 13; 7 (50): 82648-82657. doi: 10.18632/oncotarget.12244.

6. Chen X. Q. Clinicopathological significance of oestrogen receptor expression in non-small cell lung cancer., Chen X. Q., Zheng L. X., Li Z. Y., Lin T. Y., J Int Med Res. 2017 Feb; 45 (1): 51-58. doi:10.1177/0300060516666229.

7. Chenеt X. Q. Clinicopathological significance of oestrogen receptor expression in non-small cell lung cancer, Xiang-Qi Chen, Li-Xian Zheng, Zhi-Ying Li, and Ting-Yan Lin, J Int Med Res. 2017 Feb; 45 (1): 51-58. doi: 10.1177/0300060516666229.

8. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. International Agency for Research on Cancer; 2014.

9. Li-Han Hsu, Estrogen, Estrogen Receptor and Lung Cancer, Li-Han Hsu, Nei-Min Chu, and Shu-Huei Kao, Int J Mol Sci. 2017 Aug; 18 (8): 1713. Published online 2017 Aug 5. doi: 10.3390/ijms18081713.

10. Liu C.M. Potential therapeutic benefit of combining gefitinib and tamoxifen for treating advanced lung adenocarcinoma. Liu C. M., Chiu K. L., Chen T. S., Chang S. M., Yang S. Y., Chen L H., Ni Y. L., Sher Y. P., Yu S. L., 2015.

11. Lund-Iversen M, Expression of Estrogen Receptor-a and Survival in Advanced-stage Non-small Cell Lung Cancer, Lund-Iversen M, Scott H, Strom E. H., Theiss N., Brustugun O. T., Gronberg B. H. Anticancer Res. 2018 Apr; 38 (4): 2261-2269.

12. Monica V, Longo M, Felice B, Scagliotti GV, Papotti M, Novello S. Role of hormone receptor expression in patients with advanced-stage lung cancer treated with chemotherapy. Clin Lung Cancer. 2012; 13: 416-23.

13. Sheng Fan, Estrogen promotes tumor metastasis via estrogen receptor beta-mediated regulation of matrix-metalloproteinase-2 in non-small cell lung cancer // Published online 2017 Apr 10. doi: 10.18632/oncotarget.16992.

14. Sheng Fan, Yongde Liao, Changyu Liu, Quanfu Huang, Huifang Liang, Bo Ai, Shegnling Fu, and Sheng Zhou, 2017 Aug 22; 8 (34): 56443-56459.

15. Siegel R. L. Cancer statistics, 2015 / R. L. Siegel, K. D. Miller, A. Jemal // CA Cancer J. Clin.- 2015.- Vol. 65, N. 1. - P. 5-29.

16. Slowikowski B. K., Exploring estrogenic activity in lung cancer, Bartosz Kazimierz Stowikowski, Margarita Lianeri, and Pawet Piotr Jagodzihski. Mol Biol Rep. 2017; 44 (1): 35-50. doi: 10.1007/s11033-016-4086-8.

17. Vianey Rodriguez-Lara, Juan-Manuel Hernandez-Martinez, Oscar Arrieta, Influence of estrogen in non-small cell lung cancer and its clinical implications, J Thorac Dis. 2018 Jan; 10(1): 482-497.

18. Wu C. T., Chang Y. L., Shih J. Y., Lee Y. C. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J. Thorac. Cardiovasc. Surg. 2005; 130 (4): 979-986.